A PYMNTS Company

Novartis Settles Antitrust Cases Over Exforge Drug Generics

By  |  December 29, 2022

Novartis AG said it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The settlements with so-called direct purchasers, indirect purchasers and retailers require approval by a federal judge in Manhattan, and will resolve all outstanding claims against the company over the matter, Novartis said.

    Read more: Swiss Competition Watchdog Probes Novartis

    CVS Health, Kroger, Rite Aid and Walgreens Boots Alliance are among the plaintiffs in the civil litigation, which began in 2018.

    The class-action litigation stemmed from a 2011 licensing agreement between Novartis and Endo International’s Par Pharmaceutical unit.

    Novartis and Par were accused of entering an illegal “reverse payment” agreement to delay launches of less expensive, generic versions of Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.